TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 9753485
Drug: Prednisone (PRED)
Normalized name: Prednisone
DrugBank: Prednisone acetate (DB14646)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Prednisone (PRED) 40 mg once daily for the first 2 weeks tapered to 5 mg/day
Study: 10421972
Drug: L-arginine infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-arginine infusion (10% solution)
Study: 10421972
Drug: Placebo infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo infusion (5% dextrose)
Study: 402781
Drug: Intranasal disodium
Normalized name: BALSALAZIDE DISODIUM
DrugBank: Balsalazide (DB01014)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intranasal disodium cromoglycate (SCG) 40 mg/day
Study: 31488762
Drug: Duloxetine +
Approvals — FDA: no, EMA: no, PMDA: no
Description: Duloxetine + ASA (100 mg)
Study: 26031187
Drug: Ondansetron treatment
Normalized name: Ondansetron
DrugBank: Ondansetron (DB00904)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ondansetron treatment identified by IT method
Study: 26031187
Drug: Ondansetron treatment
Normalized name: Ondansetron
DrugBank: Ondansetron (DB00904)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ondansetron treatment identified by VT method
Study: 23358972
Drug: Sunitinib plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sunitinib plus FOLFIRI (37.5 mg per day, schedule 4/2)
Study: 9597554
Drug: Alprazolam (1.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alprazolam (1.0 mg)
Study: 8338086
Drug: Mesalamine 2
Normalized name: mesalamine 250 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mesalamine 2 g daily
Study: 8338086
Drug: Mesalamine 4
Normalized name: mesalamine 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mesalamine 4 g daily
Study: 25921849
Drug: Insulin infusion
Normalized name: iLet Insulin Infusion 10-Pack Kit Inset
Approvals — FDA: no, EMA: no, PMDA: no
Description: Insulin infusion with SFA + LC n-3 PUFA
Study: 21224369
Drug: PK-guided docetaxel
Normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: PK-guided docetaxel dosing
Study: 21224369
Drug: Body surface
Normalized name: hepatitis B surface antigen vaccine Injection [Recombivax]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Body surface area-based docetaxel dosing
Study: 18996055
Drug: Newly detected
Normalized name: direct blue 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Newly detected AF during the first 3 months of implant (4% incidence, 45 of 1170 patients with no AF)
Study: 18996055
Drug: History of
Normalized name: BEMOTRIZINOL 0.8 mL in 100 mL / OCTINOXATE 7 mL in 100 mL TOPICAL CREAM [THE HISTORY OF WHOO GONG JIN HYANG HAE YOON SUN]
Approvals — FDA: no, EMA: no, PMDA: no
Description: History of AF at the time of ICD implant
Study: 16868887
Drug: Optimized treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Optimized treatment for 16 weeks
Study: 9359118
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of both medications
Study: 3980805
Drug: Duo formula
Normalized name: Effaclar Duo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Duo formula group treatment (DFGT), facilitated by a fellow sufferer and a physician, in a series of ten 2-hour weekly sessions.
Study: 3980805
Drug: Duo formula
Normalized name: Effaclar Duo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Duo formula group treatment (DFGT)
Study: 29653637
Drug: Clopidogrel treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clopidogrel treatment
Study: 10490156
Drug: 50 microg
Normalized name: Digoxin 250 microgram oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 microg fentanyl in 20 ml saline
Study: 10490156
Drug: 3 mg
Normalized name: boron 3 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 mg morphine in 20 ml saline
Study: 10490156
Drug: 20 ml
Normalized name: Exact-Med, 20 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 ml saline (control)
Study: 1822216
Drug: Diltiazem preparations
Normalized name: cranberry preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diltiazem preparations
Study: 6309993
Drug: Sodium stibogluconate
Normalized name: sodium stibogluconate
DrugBank: Sodium stibogluconate (DB05630)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sodium stibogluconate (10 mg Sb/kg per dose) every 12 hr for 15 days (group B)
Study: 6309993
Drug: Sodium stibogluconate
Normalized name: sodium stibogluconate
DrugBank: Sodium stibogluconate (DB05630)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sodium stibogluconate (10 mg Sb/kg per dose) administered once daily for 31 days (group A)
Study: 6309993
Drug: Sodium stibogluconate
Normalized name: sodium stibogluconate
DrugBank: Sodium stibogluconate (DB05630)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sodium stibogluconate (10 mg Sb/kg per dose) every 8 hr for 10 days (group C)
Study: 29260804
Drug: HF +
Normalized name: Hydrofluoric acid
DrugBank: Hydrogen fluoride (DB11072)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: HF + S (10% hydrofluoric acid gel for 60 s and silane for 60 s)
Study: 29260804
Drug: Co (control,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Co (control, no surface treatment)
Study: 24934963
Drug: Doxycycline 200
Normalized name: doxycycline 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Doxycycline 200 mg plus adapalene 0.1%/benzoyl peroxide 2.5% gel (D+A/BPO)
Study: 24934963
Drug: Oral isotretinoin
Normalized name: Isotretinoin
DrugBank: Isotretinoin (DB00982)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral isotretinoin (ISO)
Study: 19602518
Drug: Individual dose
Normalized name: chloroxylenol
DrugBank: Chloroxylenol (DB11121)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Individual dose of rFSH (50-100 IU/day)
Study: 19602518
Drug: Standard dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard dose of rFSH (75 IU/day)
Study: 11289350
Drug: T4N5 liposome
Normalized name: T4N5 liposome lotion
DrugBank: Dimericine (DB17833)
Approvals — FDA: no, EMA: no, PMDA: no
Description: T4N5 liposome lotion
Study: 11289350
Drug: Placebo liposome
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo liposome lotion
Study: 8018006
Drug: Intranasal mupirocin
Normalized name: Mupirocin
DrugBank: Mupirocin (DB00410)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intranasal mupirocin calcium ointment
Study: 2920497
Drug: Adaptive control
Normalized name: ADAPT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adaptive control dosing of etoposide (dose adjustment at 28 hours based on 24-hour plasma level)
Study: 2920497
Drug: Standard dosing
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard dosing of etoposide (125 mg/m2/day)
Study: 30212951
Drug: Prophylactic oral
Normalized name: polylactic acid-polyglycolic acid copolymer
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prophylactic oral ibuprofen (10, 5, and 5 mg/kg from days 1 to 3 after birth)
Study: 30212951
Drug: Conventional ibuprofen
Normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Conventional ibuprofen treatment (same dosage from days 4 to 6 after echocardiographic confirmation of PDA on day 3)
Study: 20300016
Drug: L-Arg/L-Orn supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-Arg/L-Orn supplementation
Study: 17196132
Drug: Adefovir dipivoxil
Normalized name: Adefovir Dipivoxil
DrugBank: Adefovir dipivoxil (DB00718)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Adefovir dipivoxil (ADV) 10 mg once a day for 12 weeks, followed by 36 weeks of ADV
Study: 17196132
Drug: Lamivudine (LMV)
Normalized name: Lamivudine
DrugBank: Lamivudine (DB00709)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Lamivudine (LMV) 100 mg + Adefovir dipivoxil (ADV) 10 mg once a day for 12 weeks, followed by 36 weeks of ADV
Study: 17196132
Drug: Lamivudine (LMV)
Normalized name: Lamivudine
DrugBank: Lamivudine (DB00709)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Lamivudine (LMV) 100 mg + Placebo once a day for 12 weeks, followed by 36 weeks of ADV
Study: 15333417
Drug: HES 130
Approvals — FDA: no, EMA: no, PMDA: no
Description: HES 130 (10 mL/kg IV for 30 min)
Study: 15333417
Drug: HES 200
Approvals — FDA: no, EMA: no, PMDA: no
Description: HES 200 (10 mL/kg IV for 30 min)
Study: 15333417
Drug: Lactated Ringer's
Normalized name: LACTATED RINGER'S
DrugBank: Sodium chloride (DB09153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Lactated Ringer's solution (10 mL/kg IV for 30 min)
Study: 15333417
Drug: All test
Normalized name: All Clear
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: All test infusions (HES 130, HES 200, Lactated Ringer's)
Study: 9266259
Drug: Exogenous G-CSF
Normalized name: G-CSF
DrugBank: Lenograstim (DB13144)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Exogenous G-CSF substitution protocols
Study: 8388285
Drug: Cimetidine suspension
Normalized name: Cimetidine
DrugBank: Cimetidine (DB00501)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cimetidine suspension 200 mg
Study: 29576347
Drug: Antibiotics treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antibiotics treatment for intestinal pathogens
Study: 22537070
Drug: 10 g/d
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 g/d BSP
Study: 22537070
Drug: 5 g/d
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 g/d BSP
Study: 20458453
Drug: Rapydan patch
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rapydan patch (lidocaine-tetracaine)
Study: 20458453
Drug: EMLA patch
Normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: EMLA patch (lidocaine-prilocaine)
Study: 16448551
Drug: Concurrent chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Concurrent chemotherapy (5-FU, cisplatin, carboplatin, mitomycin C) with radiotherapy (RT)
Study: 16448551
Drug: Cisplatin-based chemotherapy
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cisplatin-based chemotherapy with RT
Study: 16448551
Drug: Carboplatin-based chemotherapy
Normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Carboplatin-based chemotherapy with RT
Study: 16448551
Drug: Mitomycin C-based
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mitomycin C-based chemotherapy with RT
Study: 14661322
Drug: Luminal 3
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Luminal 3 mg/kg
Study: 11032592
Drug: Long-term tamoxifen
Normalized name: benzethonium
DrugBank: Benzethonium (DB11125)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Long-term tamoxifen treatment (12-13 years)
Study: 11032592
Drug: Short-term tamoxifen
Normalized name: hydrogen peroxide
DrugBank: Hydrogen peroxide (DB11091)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Short-term tamoxifen treatment (2-3 years)
Study: 11032592
Drug: Long-term tamoxifen
Normalized name: benzethonium
DrugBank: Benzethonium (DB11125)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Long-term tamoxifen treatment (12-13 years) in node-positive patients
Study: 11032592
Drug: Long-term tamoxifen
Normalized name: benzethonium
DrugBank: Benzethonium (DB11125)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Long-term tamoxifen treatment (12-13 years) in estrogen receptor-positive patients
Study: 11032592
Drug: Long-term tamoxifen
Normalized name: benzethonium
DrugBank: Benzethonium (DB11125)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Long-term tamoxifen treatment (12-13 years) in estrogen receptor-negative patients
Study: 8772625
Drug: Oral propafenone,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral propafenone, mean dose of 615 ± 10 mg day-1
Study: 8772625
Drug: Oral quinidine,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral quinidine, mean dose of 1067 ± 462 mg day-1
Study: 1482282
Drug: Clomipramine (specific
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clomipramine (specific serotonin reuptake inhibitor)
Study: 15665713
Drug: DTPa-HBV-IPV/Hib vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: DTPa-HBV-IPV/Hib vaccine coadministered with 7vPn vaccine
Study: 15665713
Drug: DTPa-HBV-IPV/Hib vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: DTPa-HBV-IPV/Hib vaccine alone
Study: 2242793
Drug: Prostaglandin E2
Normalized name: Prostaglandin E2
DrugBank: Dinoprostone (DB00917)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Prostaglandin E2 suppositories 2.5 mg 1‐2 a day
Study: 321170
Drug: Intravenous iron
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous iron (iron dextran, 100 mg elemental iron)
Study: 321170
Drug: Oral iron
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral iron (ferrous sulphate, 100 mg elemental iron)
Study: 31741350
Drug: Picosecond laser
Approvals — FDA: no, EMA: no, PMDA: no
Description: Picosecond laser treatment
Study: 31741350
Drug: Lightening cream
Normalized name: HYDROQUINONE 2 g in 100 mL TOPICAL CREAM [Dark Spot Lightening Cream]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lightening cream (control)
Study: 23860050
Drug: Early feeding
Normalized name: benzyl alcohol
DrugBank: Benzyl alcohol (DB06770)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Early feeding (mean time of first oral feeding 2.5 + 0.7 days)
Study: 23860050
Drug: Late feeding
Approvals — FDA: no, EMA: no, PMDA: no
Description: Late feeding (mean time of first oral feeding 5.3 + 0.6 days)
Study: 21869636
Drug: Wobble board
Normalized name: smallpox vaccine live, New York City Board of Health vaccinia strain Injectable Solution [ACAM2000]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Wobble board balance training for 9 weeks, twice a week
Study: 8857654
Drug: 0.25 g
Normalized name: AMICAR 0.25 GM/mL Oral Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.25 g fluoride dentifrice
Study: 8857654
Drug: 1.0 g
Normalized name: IODINE 11.0 g in 1 L TOPICAL SOLUTION [T.D.]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.0 g fluoride dentifrice
Study: 26775268
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (basic antiplatelet and lipid-lowering therapy only)
Study: 22516525
Drug: Nonpharmacologic treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nonpharmacologic treatment (diet and fluid restriction)
Study: 22516525
Drug: Nonpharmacologic treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nonpharmacologic treatment (daily weighing)
Study: 22516525
Drug: Nonpharmacologic treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nonpharmacologic treatment (exercise)
Study: 18628451
Drug: Ixabepilone as
Normalized name: Ixabepilone
DrugBank: Ixabepilone (DB04845)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ixabepilone as monotherapy
Study: 11836283
Drug: Testosterone enanthate
Normalized name: Testosterone Enanthate
DrugBank: Testosterone enanthate (DB13944)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Testosterone enanthate (TE, 200 mg im weekly)
Study: 11836283
Drug: Testosterone enanthate
Normalized name: Testosterone Enanthate
DrugBank: Testosterone enanthate (DB13944)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Testosterone enanthate plus depot medroxyprogesterone acetate (DMPA, 300 mg im once)
Study: 10433577
Drug: Chromatographically purified
Normalized name: RAYON,PURIFIED
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chromatographically purified rabies vaccine (CPRV) 0.5 mL
Study: 10433577
Drug: Human diploid
Normalized name: rabies vaccine, human diploid cell
Approvals — FDA: no, EMA: no, PMDA: no
Description: Human diploid cell rabies vaccine (HDCV) 1.0 mL
Study: 2206065
Drug: Intravenous mezlocillin
Normalized name: mezlocillin
DrugBank: Mezlocillin (DB00948)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous mezlocillin for 48 hours followed by oral ampicillin until delivery
Study: 12122510
Drug: Intravenous and
Normalized name: immune globulin intravenous and subcutaneous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous and oral placebo
Study: 30413383
Drug: Neoadjuvant chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neoadjuvant chemotherapy (stage IV)
Study: 27117874
Drug: Single dose
Normalized name: Citrucel Single Dose Packets (Orange)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose of 12 mg oral dexamethasone with 4 days of placebo
Study: 27117874
Drug: 5-day course
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5-day course of oral prednisone 60 mg a day
Study: 20714145
Drug: Biapenem 300
Normalized name: biapenem
DrugBank: Biapenem (DB13028)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Biapenem 300 mg
Study: 20714145
Drug: Imipenem/cilastatin 500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Imipenem/cilastatin 500 mg/500 mg
Study: 17094981
Drug: Intravenous low-dose
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intravenous low-dose ACTH
Study: 16152759
Drug: PEG‐IFN alpha
Approvals — FDA: no, EMA: no, PMDA: no
Description: PEG‐IFN alpha 2a (180 microg per week) and RBV (1000‐1200 mg daily)
Study: 10363624
Drug: Rabeprazole 20
Normalized name: RABEprazole 20 mg oral delayed release tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rabeprazole 20 mg without antacid
Study: 10363624
Drug: Rabeprazole 20
Normalized name: RABEprazole 20 mg oral delayed release tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rabeprazole 20 mg with antacid (concomitantly)
Study: 10363624
Drug: Rabeprazole 20
Normalized name: RABEprazole 20 mg oral delayed release tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rabeprazole 20 mg one hour after antacid administration
Study: 7549753
Drug: Supplementation with
Normalized name: Similac For Supplementation with Iron Powder for Suspension
Approvals — FDA: no, EMA: no, PMDA: no
Description: Supplementation with four nutrients (vitamin A, riboflavin, zinc, and selenium), one capsule twice a week for 1 year
Study: 7549753
Drug: Placebo, one
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo, one capsule twice a week for 1 year
Study: 31943717
Drug: TAVR with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: TAVR with periprocedural anticoagulation with unfractionated heparin
Study: 26066736
Drug: Doxorubicin (75
Approvals — FDA: no, EMA: no, PMDA: no
Description: Doxorubicin (75 mg/m²) and ifosfamide (2.5 g/m²/d) on days 1-3 with mesna 500 mg/m²/dose
Study: 26066736
Drug: Gemcitabine (900
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gemcitabine (900 mg/m² on days 1, 8) and docetaxel (100 mg/m² on day 8)
Study: 15622454
Drug: CPG 7909
Approvals — FDA: no, EMA: no, PMDA: no
Description: CPG 7909 (0.125, 0.5, or 1.0 mg)
Study: 11260410
Drug: Fluvastatin (FLU)
DrugBank: Fluvastatin (DB01095)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Fluvastatin (FLU) 40 mg/day
Study: 8045978
Drug: alpha MSH
Normalized name: alpha tocopherol
Approvals — FDA: no, EMA: no, PMDA: no
Description: alpha MSH (2.5 mg as an iv bolus 60 min after the start of saline infusion)
Study: 8045978
Drug: CRH plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: CRH plus alpha MSH (injected 60 min after the start of CRH infusion)
Study: 28286971
Drug: YOMI program
Approvals — FDA: no, EMA: no, PMDA: no
Description: YOMI program (five-week intervention, twice a week)
Study: 23615640
Drug: 1 mg
Normalized name: biotin 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mg of estradiol (E2) daily for 12 weeks
Study: 23615640
Drug: 1 mg
Normalized name: biotin 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mg of estradiol (E2) and 0.5 mg of norethindrone acetate (NA) daily for 12 weeks
Study: 15276594
Drug: Interferon administered
Normalized name: Interferon Gamma
DrugBank: Interferon Gamma (DB15753)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Interferon administered three times weekly with weight-based ribavirin
Study: 15276594
Drug: Daily interferon
Normalized name: Interferon Gamma
DrugBank: Interferon Gamma (DB15753)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily interferon with weight-based ribavirin
Study: 15276594
Drug: Interferon and
Normalized name: Interferon Gamma
DrugBank: Interferon Gamma (DB15753)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Interferon and ribavirin therapy
Study: 9466164
Drug: RS-8359, oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: RS-8359, oral dosing up to 300 mg
Study: 7877116
Drug: High-risk nonusers
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-risk nonusers (thinking about using steroids)
Study: 7877116
Drug: Low-risk nonusers
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-risk nonusers (not thinking about using steroids)
Study: 7877116
Drug: Steroid users
Approvals — FDA: no, EMA: no, PMDA: no
Description: Steroid users
Study: 3282481
Drug: Clomipramine hydrochloride
Normalized name: Clomipramine Hydrochloride
DrugBank: Clomipramine (DB01242)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Clomipramine hydrochloride (maximum dosage of 300 mg/d, mean dosage at week 8 of 82.8 mg/d)
Study: 18240203
Drug: Sequential disease‐modifying
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sequential disease‐modifying antirheumatic drug monotherapy (group 1)
Study: 17405834
Drug: Step‐up combination
Approvals — FDA: no, EMA: no, PMDA: no
Description: Step‐up combination therapy (group 2)
Study: 17405834
Drug: Initial combination
Normalized name: brigatinib
DrugBank: Brigatinib (DB12267)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Initial combination therapy with tapered high‐dose prednisone (group 3)
Study: 17014731
Drug: Supervised Nordic
Normalized name: modified Vaccinia Ankara-Bavarian Nordic Injection [Jynneos]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Supervised Nordic Walking twice a week for eight weeks under supervision of a specially trained instructor
Study: 10069525
Drug: Secretin infusion
Normalized name: Secretin
DrugBank: Secretin human (DB09532)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Secretin infusion (0.1 CU/kg.h) for 60 min
Study: 10069525
Drug: Secretin +
Normalized name: Secretin
DrugBank: Secretin human (DB09532)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Secretin + CCK infusion (0.5 IDU/kg.h) for 60 min
Study: 11104404
Drug: Secretin infusion
Normalized name: Secretin
DrugBank: Secretin human (DB09532)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Secretin infusion
Study: 10069525
Drug: Secretin +
Normalized name: Secretin
DrugBank: Secretin human (DB09532)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Secretin + CCK infusion
Study: 31359519
Drug: Crocin 15
Normalized name: CROCIN
DrugBank: Crocin (DB11874)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Crocin 15 mg/day
Study: 28805758
Drug: noophen (γ‐amino‐β‐phenylbutyric
Approvals — FDA: no, EMA: no, PMDA: no
Description: noophen (γ‐amino‐β‐phenylbutyric acid hydrochloride) 15‐20 mg/kg per day (2‐3 times perorally) for 2 months
Study: 26272250
Drug: Flurbiprofen axetil
Normalized name: Flurbiprofen axetil
DrugBank: Flurbiprofen axetil (DB14938)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flurbiprofen axetil (FA) administered i.v. 15 min before skin incision in group F.
Study: 26272250
Drug: Placebo administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo administered i.v. 15 min before skin incision in group C.